Major M&A Deals Face Legal Scrutiny Over Fair Value for Shareholders
Halper Sadeh LLC, a prominent investor rights law firm, has launched investigations into three significant corporate transactions, questioning whether shareholders are receiving adequate consideration and full disclosure. The firm is examining potential securities law violations and breaches of fiduciary duty at Kezar Life Sciences ($KZR), Equitable Holdings ($EQH), and Urgent.ly ($ULYX)—deals collectively representing hundreds of millions in shareholder value. These investigations underscore growing scrutiny of merger and acquisition pricing in an environment where boards face heightened pressure to justify transaction terms.
Examination of Three Major Transactions
The three deals under investigation each present distinct circumstances that have prompted questions about shareholder treatment:
Kezar Life Sciences Acquisition: The pharmaceutical company is being acquired by Aurinia Pharmaceuticals for $6.955 per share plus a contingent value right (CVR). This structure—common in pharmaceutical deals where pipeline assets carry uncertain future value—creates questions about the true economic value shareholders will ultimately receive. CVRs are often criticized for leaving shareholders exposed to execution risk while limiting upside participation if pipeline candidates succeed commercially.
Equitable Holdings Merger: In a stock-for-stock combination with Corebridge Financial, Equitable shareholders will own approximately 49% of the combined entity. This deal structure—particularly the nearly equal ownership split—raises questions about valuation methodologies and whether the stock exchange ratio adequately reflects relative company values. The use of stock consideration introduces currency risk and ongoing shareholder exposure to combined entity performance, requiring thorough fairness analyses.
Urgent.ly Sale: The platform is being sold to Agero for $5.50 per share. The relatively specific per-share price suggests a fixed valuation, which may or may not reflect current market conditions and the company's growth trajectory.
Market Context and Deal Environment
These investigations arrive during a period of significant M&A activity following the technology and interest rate-driven disruptions of 2022-2023. The scrutiny reflects several important trends:
Heightened Shareholder Activism: Investor rights firms have become increasingly vigilant about transaction pricing, particularly as deal volumes recover. This environment has created a new baseline expectation that merger transactions will face legal examination regarding fairness opinions, process quality, and disclosure completeness.
Sector-Specific Pressures: The pharmaceutical sector (relevant to the Kezar deal) has faced particular scrutiny over acquisition valuations, with shareholders questioning whether companies with promising pipelines are being undervalued. The insurance and financial services sectors, where both Equitable and Corebridge operate, face their own valuation complexities given regulatory requirements and capital structure considerations.
Process and Disclosure Concerns: Halper Sadeh is specifically seeking not only increased consideration but also additional disclosures. This dual focus suggests the firm may view the original processes as insufficiently transparent regarding valuation methodologies, alternative strategic options, or comparable transaction benchmarks.
Investor Implications and What's at Stake
For shareholders of the three companies involved, these investigations carry concrete implications:
Potential Deal Repricing: Successful investor rights litigation has resulted in material price increases in numerous M&A transactions. If Halper Sadeh's investigations gain traction, shareholders could see improved terms before deals close, though this outcome remains uncertain and depends on multiple factors.
Timeline and Execution Risk: Legal challenges to merger agreements can delay closings, create regulatory complications, or require renegotiation of terms. Shareholders should monitor these investigations closely, as they may impact deal certainty and timing.
Broader Market Signaling: These simultaneous investigations send a message to corporate boards and transaction advisors that M&A process quality and pricing will face increased scrutiny. This may influence future deal structuring and require more rigorous fairness opinions and disclosure.
Class Action Considerations: The investigation by Halper Sadeh may precede formal class action litigation. Shareholders interested in joining such actions should monitor the firm's announcements and regulatory filings.
The financial magnitude of these deals—while the exact aggregate value isn't specified in available documents—involves material shareholder interests. For EQH and ULYX shareholders particularly, improvements in deal terms could represent significant percentage gains on their holdings.
Looking Forward
These three transactions serve as reminders that modern M&A scrutiny extends well beyond initial announcement coverage. Halper Sadeh LLC's investigations will likely evolve over coming weeks and months, with potential outcomes ranging from additional disclosures and modest repricing to more substantial deal restructurings. The firm's dual focus on consideration levels and disclosure quality reflects the sophistication of contemporary shareholder advocacy.
Investors holding positions in KZR, EQH, or ULYX should remain alert to announcements regarding these investigations. The outcomes may materially affect deal terms and ultimate shareholder value realization. Meanwhile, the broader investment community should recognize that deal pricing and process quality have become standard subjects for post-announcement scrutiny—a development that may ultimately benefit shareholders through more rigorous transaction oversight.